Advertisement

Search Results

Advertisement



Your search for Bishoy M. Faltas, MD matches 9 pages

Showing 1 - 9


Bishoy Faltas, MD, Named Chief Research Officer of the Englander Institute for Precision Medicine at Weill Cornell Medicine

Olivier Elemento, PhD, Director of the Englander Institute for Precision Medicine (EIPM) at Weill Cornell Medicine, New York, recently announced that Bishoy M. Faltas, MD, has been named Chief Research Officer of EIPM effective immediately. EIPM is a large multidisciplinary institute that uses...

bladder cancer

Bishoy M. Faltas, MD, on Upper Tract Urothelial Carcinoma: How Biology Shapes Therapy

Bishoy M. Faltas, MD, of Weill Cornell Medicine, discusses the biology of upper tract urothelial carcinoma and how it affects treatment, noting that most of these tumors are luminal papillary with a T-cell–depleted immune contexture driven by FGFR3 activation. Phase III trials have confirmed the...

bladder cancer
kidney cancer
prostate cancer
immunotherapy

Genitourinary Oncology 2021–2022 Almanac

The past year has witnessed tremendous advances in genitourinary oncology. I am pleased to review these findings in this year’s Genitourinary Oncology Almanac from The ASCO Post. I hope that you will find this roadmap helpful in highlighting a selection of these exciting developments. Checkpoint...

bladder cancer
genomics/genetics

Germline-Somatic Interactions in Advanced Urothelial Cancer and Their Role in Disease Progression

In a study reported in Nature Communications, Bishoy M. Faltas, MD, of the Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, and colleagues identified common germline-somatic variant interactions in advanced urothelial cancer, with these...

bladder cancer
genomics/genetics

Spectrum of Germline-Somatic Interactions in Advanced Urothelial Cancer

In a study reported in Nature Communications, Vosoughi et al identified common germline-somatic variant interactions in advanced urothelial cancer, with these interactions appearing to play a central role in disease progression. As stated by the investigators, “The prevalence and the biologic...

genomics/genetics
bladder cancer

Study Identifies Factors in Clonal Evolution of Chemotherapy-Resistant Urothelial Carcinoma

In a study reported in Nature Genetics, Bishoy M. Faltas, MD, of Weill Cornell Medicine, and colleagues identified factors in the clonal evolution of chemotherapy-resistant urothelial carcinoma.1 As stated by the investigators: “Chemotherapy-resistant urothelial carcinoma has no uniformly curative...

solid tumors

Factors in Clonal Evolution of Chemotherapy-Resistant Urothelial Carcinoma Identified

Faltas et al identified factors in the clonal evolution of chemotherapy-resistant urothelial carcinoma, according to a study reported in Nature Genetics. Findings included wide intrapatient mutational heterogeneity and enrichment for clonal mutations involving L1 cell–adhesion molecule...

Conquer Cancer Foundation Honors 74 Oncologists for Contributions to Genitourinary Cancer, Cancer Survivorship, Gastrointestinal Cancer, and Quality Care Research

The Conquer Cancer Foundation of ASCO is pleased to announce the recipients of its 2016 Conquer Cancer Foundation of ASCO Merit Awards in Gastrointestinal Cancer, Genitourinary Cancer, Cancer Survivorship, and Quality Care. The following 74 young investigators, recognized for the scientific merit...

solid tumors

Bishoy M. Faltas, MD, on Advanced Urothelial Carcinoma: Generating a Neoantigen Map

Bishoy M. Faltas, MD, of Weill Cornell Medical College, discusses his team’s work using whole exome sequencing, which may have important implications for selecting patients for immunotherapeutic approaches (Abstract 354).

Advertisement

Advertisement




Advertisement